FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981397214> ?p ?o ?g. }

• W2981397214 abstract "Abstract Background The use of beta-blockers for treatment of heart failure (HF) with a reduced ejection fraction (EF) is unequivocally beneficial, but their role in the treatment of preserved EF (HFpEF) remains unclear. Purpose In a contemporary HFpEF cohort, we sought to assess the association of HF hospitalizations and the use of beta-blockers in patients with an EF above and below 50%. Methods The TOPCAT trial tested spironolactone vs. placebo among patients with HFpEF, including some with mild reductions in EF between 45–50%. The primary outcome was a composite of cardiovascular (CV) mortality, aborted cardiac arrest, or HF hospitalizations. Medication use, including beta-blockers, was reported at each visit and hospitalization. In the 1,761 participants from the Americas, we compared the association of beta-blocker use (vs. no use) and HF hospitalization or CV mortality using Cox proportional hazards models adjusted for baseline demographics, history of myocardial infarction, atrial fibrillation, chronic obstructive pulmonary disease, asthma, and hypertension. The analyses were repeated in the EF strata ≥50% and <50%. Results Among patients included in the current analysis (mean age 72 years, 50% female, 78% white), 1,496/1,761 (85%) received beta-blockers and 1,566/1,761 (89%) had an EF ≥50%. HF hospitalizations and CV mortality occurred in 399/1,761 (23%) and 223/1,761 (13%) of participants, respectively. Beta-blocker use was associated with an increase in risk of HF hospitalization among patients with preserved EF ≥50% [HR 1.56, (95% CI 1.09–2.24), p=0.01] and was associated with a reduction in risk of hospitalization in patients with an EF <50% [HR 0.42, (95% CI 0.18- 0.99), p<0.05]. We found a significant interaction for EF threshold and beta-blocker use on incident HF hospitalizations (p=0.01). There were no differences in CV mortality. Figure 1. Kaplan Meier incidence plots Conclusions Beta-blocker use was associated with an increase in HF hospitalizations in patients with HFpEF (EF≥50%) but did not affect CV mortality. Further research is needed to confirm these findings and elucidate causality." @default.
• W2981397214 created "2019-11-01" @default.
• W2981397214 creator A5001743370 @default.
• W2981397214 creator A5009322495 @default.
• W2981397214 creator A5022058899 @default.
• W2981397214 creator A5032614493 @default.
• W2981397214 creator A5056254705 @default.
• W2981397214 creator A5062357943 @default.
• W2981397214 date "2019-10-01" @default.
• W2981397214 modified "2023-09-27" @default.
• W2981397214 title "P1666Do beta-blockers increase the risk for hospitalizations in heart failure with preserved ejection fraction? A secondary analysis of beta-blocker use in the TOPCAT trial" @default.
• W2981397214 doi "https://doi.org/10.1093/eurheartj/ehz748.0424" @default.
• W2981397214 hasPublicationYear "2019" @default.
• W2981397214 type Work @default.
• W2981397214 sameAs 2981397214 @default.
• W2981397214 citedByCount "0" @default.
• W2981397214 crossrefType "journal-article" @default.
• W2981397214 hasAuthorship W2981397214A5001743370 @default.
• W2981397214 hasAuthorship W2981397214A5009322495 @default.
• W2981397214 hasAuthorship W2981397214A5022058899 @default.
• W2981397214 hasAuthorship W2981397214A5032614493 @default.
• W2981397214 hasAuthorship W2981397214A5056254705 @default.
• W2981397214 hasAuthorship W2981397214A5062357943 @default.
• W2981397214 hasConcept C126322002 @default.
• W2981397214 hasConcept C164705383 @default.
• W2981397214 hasConcept C199360897 @default.
• W2981397214 hasConcept C2776174256 @default.
• W2981397214 hasConcept C2778198053 @default.
• W2981397214 hasConcept C2778742482 @default.
• W2981397214 hasConcept C41008148 @default.
• W2981397214 hasConcept C71924100 @default.
• W2981397214 hasConcept C78085059 @default.
• W2981397214 hasConceptScore W2981397214C126322002 @default.
• W2981397214 hasConceptScore W2981397214C164705383 @default.
• W2981397214 hasConceptScore W2981397214C199360897 @default.
• W2981397214 hasConceptScore W2981397214C2776174256 @default.
• W2981397214 hasConceptScore W2981397214C2778198053 @default.
• W2981397214 hasConceptScore W2981397214C2778742482 @default.
• W2981397214 hasConceptScore W2981397214C41008148 @default.
• W2981397214 hasConceptScore W2981397214C71924100 @default.
• W2981397214 hasConceptScore W2981397214C78085059 @default.
• W2981397214 hasLocation W29813972141 @default.
• W2981397214 hasOpenAccess W2981397214 @default.
• W2981397214 hasPrimaryLocation W29813972141 @default.
• W2981397214 hasRelatedWork W110249100 @default.
• W2981397214 hasRelatedWork W1800455779 @default.
• W2981397214 hasRelatedWork W1964830208 @default.
• W2981397214 hasRelatedWork W2025343611 @default.
• W2981397214 hasRelatedWork W2289709123 @default.
• W2981397214 hasRelatedWork W2346789491 @default.
• W2981397214 hasRelatedWork W2413317322 @default.
• W2981397214 hasRelatedWork W2611031506 @default.
• W2981397214 hasRelatedWork W2655194081 @default.
• W2981397214 hasRelatedWork W2782438197 @default.
• W2981397214 hasRelatedWork W2808127910 @default.
• W2981397214 hasRelatedWork W2901944982 @default.
• W2981397214 hasRelatedWork W2943814025 @default.
• W2981397214 hasRelatedWork W2950383051 @default.
• W2981397214 hasRelatedWork W2989757864 @default.
• W2981397214 hasRelatedWork W2996692369 @default.
• W2981397214 hasRelatedWork W3032078057 @default.
• W2981397214 hasRelatedWork W3095284247 @default.
• W2981397214 hasRelatedWork W3192484920 @default.
• W2981397214 hasRelatedWork W3207252657 @default.
• W2981397214 isParatext "false" @default.
• W2981397214 isRetracted "false" @default.
• W2981397214 magId "2981397214" @default.
• W2981397214 workType "article" @default.